Laboratory of Surgical Research, Department of Surgery North Shore University Hospital and Long Island Jewish Medical Center, The Feinstein Institute for Medical Research, Manhasset, NY 11030, USA.
Int J Mol Med. 2010 Jan;25(1):159-64.
Hepatocellular dysfunction occurs early in sepsis and this appears to be caused by Kupffer cell-derived TNF-alpha production from the liver as a result of the increased release of the sympathetic neurotransmitter, norepinephrine, from the gut. Ghrelin, a novel stomach-derived peptide, is down-regulated in sepsis and administration of ghrelin into rodents decrease pro-inflammatory cytokines, attenuates hepatic and other organ injuries and improves survival. Ghrelin's beneficial effect in sepsis is mediated by the inhibition of the sympathetic nervous system (SNS), as evidenced by the reduced gut-derived norepineprine (NE) release in sepsis after ghrelin treatment. Recent data suggest that MKP-1, the MAPK phosphatase-1, is involved in the innate immune responses. To determine that the beneficial effect of ghrelin in sepsis is mediated by MKP-1, rats were subjected to sepsis by cecal ligation and puncture (CLP) alone, or treated with ghrelin, beginning at 5-h post-CLP and liver tissues were harvested and examined for MKP-1 mRNA and protein expression. CLP alone produced a significant decrease in MKP-1 gene expression in liver tissues at 20 h after CLP (P<0.05). MKP-1 mRNA was decreased by 30-40% at 2 and 5 h after CLP, but not statistically significant. MKP-1 protein expression was significantly decreased as early as 2 h after CLP and remained low at 5-20 h after CLP. While septic rats treated with vehicle produced significant decreases from sham rats, ghrelin treatment improved both mRNA and protein from vehicle group (0.58+/-0.069 vs. 0.91+/-0.16, P<0.05; 0.14+/-0.027 vs. 0.22+/-0.017, P=0.013), respectively. Since ghrelin's inhibitory effect is mediated by the SNS, we hypothesized that NE treatment in Kupffer cells may downregulate MKP-1. Kupffer cells were treated with NE and examined for MKP-1. Treatment with NE for 60 min showed an average of 46.9% decrease in MKP-1 mRNA expression compared to untreated cells (P<0.001). Likewise, NE treatment in RAW264.7 cells produced significantly lower MKP-1 mRNA than that of control cells. To further confirm the effect of NE on MKP-1, normal rats were infused with NE for 2 h through the portal vein and MKP-1 mRNA from the liver was examined. Infusion with NE produced a significant 73.7% decrease in MKP-1 mRNA. Therefore, ghrelin's inhibitory effect on gut-derived NE release in sepsis leading to the downregulation of pro-inflammatory cytokines is mediated by MKP-1.
肝细胞功能障碍在脓毒症早期发生,这似乎是由于肠道中交感神经递质去甲肾上腺素的释放增加,导致库普弗细胞产生 TNF-α。胃泌素是一种新型的胃来源肽,在脓毒症中下调,给予胃泌素可减少促炎细胞因子,减轻肝和其他器官损伤,提高存活率。胃泌素在脓毒症中的有益作用是通过抑制交感神经系统(SNS)介导的,这可以通过脓毒症后胃泌素治疗减少肠道来源的去甲肾上腺素(NE)释放来证明。最近的数据表明,MAPK 磷酸酶-1(MKP-1)参与了固有免疫反应。为了确定胃泌素在脓毒症中的有益作用是通过 MKP-1 介导的,将大鼠通过盲肠结扎和穿刺(CLP)单独或用胃泌素治疗,从 CLP 后 5 小时开始,采集肝组织并检查 MKP-1 mRNA 和蛋白表达。CLP 单独在 CLP 后 20 小时导致肝组织中 MKP-1 基因表达显著降低(P<0.05)。CLP 后 2 和 5 小时,MKP-1 mRNA 降低了 30-40%,但无统计学意义。MKP-1 蛋白表达早在 CLP 后 2 小时就显著降低,在 CLP 后 5-20 小时仍保持低水平。虽然用载体治疗的败血症大鼠与假手术大鼠相比显著减少,但胃泌素治疗分别改善了载体组的 mRNA 和蛋白(0.58+/-0.069 与 0.91+/-0.16,P<0.05;0.14+/-0.027 与 0.22+/-0.017,P=0.013)。由于胃泌素的抑制作用是通过 SNS 介导的,我们假设 NE 处理库普弗细胞可能会下调 MKP-1。用 NE 处理库普弗细胞并检查 MKP-1。用 NE 处理 60 分钟与未处理细胞相比,MKP-1 mRNA 表达平均降低 46.9%(P<0.001)。同样,RAW264.7 细胞中的 NE 处理产生的 MKP-1 mRNA 明显低于对照细胞。为了进一步证实 NE 对 MKP-1 的影响,通过门静脉向正常大鼠输注 NE 2 小时,并检查肝内 MKP-1 mRNA。NE 输注可使 MKP-1 mRNA 显著降低 73.7%。因此,胃泌素在脓毒症中抑制肠道来源的 NE 释放导致促炎细胞因子下调,是通过 MKP-1 介导的。